Posted: Tuesday, January 21, 2025
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) announced the awarding of new quality improvement research grants aimed at advancing care for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). These projects will be overseen by the NCCN Oncology Research Program, with funding provided through support from AstraZeneca.
“Despite advances in treatment, many patients with CLL/SLL, particularly those from underserved communities, are not receiving care that aligns with current clinical guidelines. We are hoping to increase access to optimal care in order to improve outcomes and the overall quality of life for these patients,” explained Crystal S. Denlinger, MD, Chief Executive Officer, NCCN. “We congratulate these researchers and look forward to seeing their contributions make a tangible difference in future care for CLL/SLL patients.”
Here are the selected researchers and their projects:
The NCCN ORP fosters innovation and knowledge discovery that improve the lives of people with cancer and supports preclinical, translational, and clinical research and quality improvement projects in oncology at NCCN member institutions. To improve collaboration in cancer research, the NCCN ORP also maintains a shared resources website, an informed consent database, and points to consider on the best practices for biorepositories, registries, and databases. For more information, visit NCCN.org/orp.
National Comprehensive Cancer Network